Chromadex Corp Stock Net Asset
CDXC Stock | USD 6.71 0.11 1.67% |
Chromadex Corp fundamentals help investors to digest information that contributes to Chromadex Corp's financial success or failures. It also enables traders to predict the movement of Chromadex Stock. The fundamental analysis module provides a way to measure Chromadex Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chromadex Corp stock.
Chromadex | Net Asset |
Chromadex Corp Company Net Asset Analysis
Chromadex Corp's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Chromadex Corp Net Asset | 54.96 M |
Most of Chromadex Corp's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chromadex Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Chromadex Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Chromadex Corp is extremely important. It helps to project a fair market value of Chromadex Stock properly, considering its historical fundamentals such as Net Asset. Since Chromadex Corp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Chromadex Corp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Chromadex Corp's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
Chromadex Total Assets
Total Assets |
|
Based on the recorded statements, Chromadex Corp has a Net Asset of 54.96 M. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Chromadex Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chromadex Corp's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chromadex Corp could also be used in its relative valuation, which is a method of valuing Chromadex Corp by comparing valuation metrics of similar companies.Chromadex Corp is currently under evaluation in net asset category among its peers.
Chromadex Corp ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Chromadex Corp's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Chromadex Corp's managers, analysts, and investors.Environmental | Governance | Social |
Chromadex Corp Institutional Holders
Institutional Holdings refers to the ownership stake in Chromadex Corp that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Chromadex Corp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Chromadex Corp's value.Shares | Winton Capital Group Ltd | 2024-09-30 | 178.1 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 175.2 K | Arrowstreet Capital Limited Partnership | 2024-09-30 | 170.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 163.6 K | Bank Of New York Mellon Corp | 2024-09-30 | 155.2 K | Goldman Sachs Group Inc | 2024-09-30 | 145 K | Gamco Investors, Inc. Et Al | 2024-09-30 | 143.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 140.2 K | Ameriprise Financial Inc | 2024-09-30 | 105.6 K | Vanguard Group Inc | 2024-09-30 | 3.4 M | Blackrock Inc | 2024-06-30 | 3.1 M |
Chromadex Fundamentals
Return On Equity | 0.0482 | ||||
Return On Asset | 0.0051 | ||||
Profit Margin | 0.02 % | ||||
Operating Margin | 0.06 % | ||||
Current Valuation | 483.18 M | ||||
Shares Outstanding | 76.38 M | ||||
Shares Owned By Insiders | 35.39 % | ||||
Shares Owned By Institutions | 23.95 % | ||||
Number Of Shares Shorted | 2 M | ||||
Price To Earning | (19.51) X | ||||
Price To Book | 14.91 X | ||||
Price To Sales | 5.37 X | ||||
Revenue | 83.57 M | ||||
Gross Profit | 42.8 M | ||||
EBITDA | (3.89 M) | ||||
Net Income | (4.94 M) | ||||
Cash And Equivalents | 16.87 M | ||||
Cash Per Share | 0.25 X | ||||
Total Debt | 3.28 M | ||||
Debt To Equity | 0.22 % | ||||
Current Ratio | 2.17 X | ||||
Book Value Per Share | 0.45 X | ||||
Cash Flow From Operations | 7.12 M | ||||
Short Ratio | 0.72 X | ||||
Earnings Per Share | 0.02 X | ||||
Target Price | 7.96 | ||||
Number Of Employees | 106 | ||||
Beta | 1.88 | ||||
Market Capitalization | 492.67 M | ||||
Total Asset | 54.96 M | ||||
Retained Earnings | (190.46 M) | ||||
Working Capital | 28.91 M | ||||
Current Asset | 16.55 M | ||||
Current Liabilities | 9.59 M | ||||
Net Asset | 54.96 M |
About Chromadex Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chromadex Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chromadex Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chromadex Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chromadex Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromadex Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromadex Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromadex Corp Stock:Check out Chromadex Corp Piotroski F Score and Chromadex Corp Altman Z Score analysis. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.02 | Revenue Per Share 1.215 | Quarterly Revenue Growth 0.312 | Return On Assets 0.0051 | Return On Equity 0.0482 |
The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.